# US 2025/0368656 A1 · Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- Enenitrile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368656 A1
- Document ID: US20250368656A1
- Status: Published application
- Kind: A1
- Application number: 19/208,781
- Filed: 2025-05-15
- Published: 2025-12-04
- Earliest claimed: 2020-01-22
- Assignees: Principia Biopharma Inc.
- Applicants: Principia Biopharma Inc.
- Inventors: Pasit Phiasivongsa; Kolbot By; Jean Baum
- Web page: https://patentgrep.com/patent/US20250368656A1

## CPC

- C07D 487/14: Ortho-condensed systems
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 487/04: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A process of preparing crystalline Form A of Compound (I):
wherein C* is a stereochemical center, and
wherein crystalline Form A is characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 5.6±0.2, 12.7±0.2, 16.5±0.2, 17.0±0.2, 17.7±0.2, 18.7±0.2, 19.2±0.2, 20.7±0.2, 22.2±0.2, and 24.4±0.2,
the process comprising:
adding isopropyl acetate to amorphous (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile to form a solution;
agitating the solution to form a precipitate; and
isolating crystalline Form A by filtration.

### Claim at position 3

10-33. (canceled)

### Claim 34 (depends on 9)

A pharmaceutical composition comprising:
crystalline Form A of Compound (I) prepared by the process of claim 9; and
at least one pharmaceutically acceptable excipient.

### Claim 35 (depends on 34)

The pharmaceutical composition according to claim 34, wherein the pharmaceutical composition is in the form of a solid oral composition.

### Claim 36 (depends on 34)

The pharmaceutical composition according to claim 34, wherein the pharmaceutical composition is in the form of a tablet or a capsule.

### Claim 37 (depends on 9)

A method of inhibiting Bruton's tyrosine kinase (BTK) in a mammal comprising administering to the mammal in need of said BTK inhibition a therapeutically effective amount of crystalline Form A of Compound (I) prepared by the process of claim 9.

### Claim 38 (depends on 9)

A method of treating a disease mediated by Bruton's tyrosine kinase (BTK) in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of crystalline Form A of Compound (I) prepared by the process of claim 9.

### Claim 39 (depends on 9)

A method of treating a disease in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of crystalline Form A of Compound (I) prepared by the process of claim 9, wherein the disease is chosen from at least one of Pemphigus vulgaris, Pemphigus foliaceus, immune thrombocytopenia, asthma, and dermatitis.

### Claim 40

(canceled)

### Claim 41 (depends on 37)

The method of claim 37, wherein the mammal is a human.

### Claim 42 (depends on 38)

The method of claim 38, wherein the mammal is a human.

### Claim 43 (depends on 39)

The method of claim 39, wherein the mammal is a human.
